anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Silicosis represents a paramount occupational health hazard globally, with its incidence, morbidity, and mortality on an upward trajectory, posing substantial clinical dilemmas due to limited effective treatment options available. Trigonelline (Trig), a plant alkaloid extracted mainly from coffee and fenugreek, have diverse biological properties such as protecting dermal fibroblasts against ultraviolet radiation and has the potential to inhibit collagen synthesis. However, it's unclear whether Trig inhibits fibroblast activation to attenuate silicosis-induced pulmonary fibrosis is unclear.
METHODS: To evaluate the therapeutic efficacy of Trig in the context of silicosis-related pulmonary fibrosis, a mouse model of silicosis was utilized. The investigation seeks to elucidated Trig's impact on the progression of silica-induced pulmonary fibrosis by evaluating protein expression, mRNA levels and employing Hematoxylin and Eosin (H&E), Masson's trichrome, and Sirius Red staining. Subsequently, we explored the mechanism underlying of its functions.
RESULTS: In vivo experiment, Trig has been demonstrated the significant efficacy in mitigating SiO2-induced silicosis and BLM-induced pulmonary fibrosis, as evidenced by improved histochemical staining and reduced fibrotic marker expressions. Additionally, we showed that the differentiation of fibroblast to myofibroblast was imped in Trig + SiO2 group. In terms of mechanism, we obtained in vitro evidence that Trig inhibited fibroblast-to-myofibroblast differentiation by repressing TGF-β/Smad signaling according to the in vitro evidence. Notably, our finding indicated that Trig seemed to be safe in mice and fibroblasts.
CONCLUSION: In summary, Trig attenuated the severity of silicosis-related pulmonary fibrosis by alleviating the differentiation of myofibroblasts, indicating the development of novel therapeutic approaches for silicosis fibrosis.
No infusion pump is presently available which is able to obtain drug libraries from different types of drug library editors, e.g., from both dedicated DLEs and enterprise DLEs. Although in the case of enterprise DLEs, one OLE may be used with different types of infusion pumps, no infusion pump can receive drug libraries from more than one OLE even though one infusion pump type can be used in different settings, such as the home or hospital. In present practice, one infusion pump can receive a drug library from one specified type of drug library editor, but no other. For example, one infusion pump can receive a drug library from an enterprise drug library editor, but not a dedicated drug library editor. Similarly, a different kind of infusion pump can receive a drug library from a dedicated drug library editor, but not an enterprise drug library editor. Thus, the manufacturer must produce and the users must select different infusion pumps and associated DLEs for different applications, increasing cost and complexity. Different programming is required for dedicated DLEs and enterprise DLEs, increasing the confusion and effort required for programmers of different DLEs. Healthcare systems which cover multiple levels of care from home care to hospital care must maintain different DLEs for different levels, increasing costs to the healthcare system and to the consumers. Accordingly, the present invention provides an infusion pump system and method with multiple drug library editor source capability including: an infusion pump system having a first drug library editor operable to generate a first drug library; a second drug library editor operable to generate a second drug library; and an infusion pump configured to connect with the first drug library editor and the second drug library editor, the first drug library editor different than the second drug library editor. The infusion pump having an operational drug library for use during operation of the infusion pump, said operational drug library can be selected from one of the first drug library received from the first drug library editor and the second drug library received from the second drug library editor. The first drug library editor is a dedicated drug library editor, and the second drug library editor is the enterprise drug library editor. The infusion pump is configured to identify whether the operational drug library comes from the first drug library editor or the second drug library editor based on a configuration setting.
ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness. ARFI US has been shown in a small pilot investigation in Europe in children to be reliable and rapid in estimating moderate to severe liver stiffness using histology as a reference gold standard. ARFI measures the speed of a shear wave in the examined tissue, expressed in m/s. This shear wave velocity can be mathematically converted into a liver stiffness value, which can then be used to estimate degree of liver fibrosis. The technique is non-invasive, uses no ionizing radiation, and is fast (several minutes to complete). It is possible that ARFI US will be more accurate than MRE in quantifying liver stiffness. In addition, ARFI US will ultimately be a less expensive clinical test, shorter in duration, and will not require sedation/anesthesia in younger children as MRE requires.
PURPOSE:To obtain a dermatic agent effective to improve the blood flow acceleration effect of carbon dioxide gas, by combining carbon dioxide gas (generating substance) and oxygen gas (generating substance). CONSTITUTION:The objective agent can be produced by combining (A) carbon dioxide gas or a substance capable of generating carbon dioxide gas (e.g. a combination of a carbonate and an acid) and (B) oxygen gas or a substance capable of generating oxygen gas (e.g. sodium perborate) in a manner to generate >=60ppm of carbon dioxide gas and >=300ppm of oxygen gas. The agent is effective to improve the wound-curing promotion effect of a dermatic drug for external use, the moistening effect of cosmetic to the skin and hair, and the fatigue-restoration effect and shoulder discomfort remedying effect of bathing agent. The agent is used either by (i) dissolving carbon dioxide gas and oxygen gas in a base and sealing the base in a closed vessel, (ii) adsorbing carbon dioxide gas and oxygen gas in respective carrier (e.g. zeolite) and compounding the carriers to a base, or (iii) compounding the substances generating each gas to a base and reacting the substances at need, or their arbitrary combination.
The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
The present invention relates to a making method of chewing gum used for preventing decayed teeth. The chewing gum is prepared from tea juice, syrup, gum matrix and refined sugar powder, wherein the tea juice contains tea fluoride which can prevent decayed teeth. The making method of the chewing gum comprises the following steps: soaking, boiling and concentrating tea; mixing the tea juice, the syrup, the gum matrix and the refined sugar powder; molding the mixture, etc. The selection of the tea need to noticing, and the dosage and the processing temperature of the tea fluoride are well controlled during the course of making. Compared with foreign sodium fluoride chewing gum, the chewing gum containing tea has the advantages of long effective acting time on tooth, favorable effect, no poison, no harm and no side effect. When used, the chewing gum of the present invention does not need the guidance of doctors and the urgence of parents, and therefore, the present invention is good food for preventing decayed teeth. Simultaneously, the chewing gum of the present invention can promote the development of bones and muscle of the maxillofacial regions of children by chawing.
A dental caries preventive; for once daily self-applied topical use. It is well established that 1.1% sodium fluoride is safe and extraordinarily effective as a caries preventive when applied frequently with mouthpiece applicators. 1-4 PreviDent® 5000 BoosterPlus brand of 1.1% sodium fluoride toothpaste in a squeeze bottle is easily applied onto a toothbrush. This prescription toothpaste should be used once daily in place of your regular toothpaste unless otherwise instructed by your dental professional. May be used in areas where drinking water is fluoridated since topical fluoride cannot produce fluorosis. (See WARNINGS for exception.)
The invention relates to a medical flocking hemostasis material for stopping bleeding and protecting arteries, veins and wounds of tissues, application of the medical flocking hemostasis material and a method for preparing the medical flocking hemostasis material. The medical flocking hemostasis material comprises a flocking layer and a base layer, the flocking layer is used as a wound contacting layer and made of functional fibers, and the functional fibers are fixed on the upper surface of the base layer in a flocking method. The flocking method comprises a mechanical flocking method and an electrostatic flocking method. The medical flocking hemostasis material can be used for stopping bleeding and protecting the arteries, the veins and the wounds of the tissues, and further can be used as a medicine slow-release carrier. The invention further discloses method for controlling bleeding of the arteries, bleeding of the veins and bleeding of the wounds of the tissues by the aid of the medical flocking hemostasis material. Compared with a hemostasis material in the prior art, the medical flocking hemostasis material has the advantages that a hemostasis performance, comfortableness and the like are greatly improved.
PURPOSE:To obtain an atoxic dentifrice maintaining a refreshing feeling for a long time after cleaning, effective for preventing a bad breath and suppressing adhesion of coating of tongue, containing capsaicine as an active ingredient. CONSTITUTION:A dentifrice is blended with >=10ppm capsaicine which is a hot composition contained in the pericap of Capsicum annum L. such as Capsicum annum L. var. parvo-aqiminatum Makino, Capsicum annum L. var. fasciculatum Irish or FUSHIMI and shown by the formula, as an active ingredient to give a dentifrice contributing to hygiene of oral cavity, having the above- mentioned effects and effective for removing a bad breath and coating of tongue. Not only pure capsaicine but also essence of hot Capsicum annum L. extracted with an alcohol, an ether or benzene or a capsaicine-containing substance such as powder of dried fruit of hot Capsicum annum L. can be used as the active ingredient and properly the amount of the active ingredient is 2-3% based on the total amount of dentifrice in the case of Capsicum annum L. var. parvo- aqiminatum Makino and about 2.5-3.5% in the case of Capsicum annum L. var. fasciculatum Irish.
1462442 Purification of patricin SPA SOC PRODOTTI ANTIBIOTICI SpA 27 Aug 1975 [29 Aug 1974] 37773/74 Heading C2A A process for the recovery of patricin comprises adding a surface-active agent to a fermented liquor containing patricin in an amount sufficient to bring the patricin into solution, removing insoluble material and recovering patricin from the aqueous solution. The surface active agent may be a cationic agent such as an alkyl aryl ammonium salt, or an anionic agent such as an alkali metal alkyl sulphate. The patricin may be recovered by precipitation from solution by the addition of a metal salt, suitably an alkaline earth metal salt. The surface-active agent may be removed from the precipitated patricin by treatment with a suitable solvent or with a surface-active agent of the opposite type to that initially used. Alternatively the patricin may be isolated from the treated fermentation liquor by treatment with at least 5% by volume of a solvent which is water-immiscible and with a surface-active agent of the opposite type to that initially used. The patricin isolated by these methods may be further purified by solubilization followed by reprecipitation upon the addition of a non- solvent for patricin.
The novel compounds correspond to the formula: <IMAGE> in which X, Y, Z, R1, R2, R3 and U have the meanings given in Claim 1. They are prepared by reacting 1 mol equivalent of an appropriate compound I or II, in which the -NH-CX-NR2R3 radical is replaced by -NCX, with 1 to 1.5 mol equivalents of HNR2R3 or its acid addition salt. The reaction is carried out in a solvent at 0 to 100 DEG C. Compounds of the formula I, in which X denotes oxygen and Y, Z and R1 denote hydrogen and U denotes the carbonyl radical and R2 and R3 have the meanings given in Claim 4, are prepared from 4-amino-7-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene hydrochloride. This is reacted with phosgene at reflux temperature. Benzene, toluene, xylene or a mixture of isomeric xylenes is used in this reaction as a solvent, and one mol equivalent of the isocyanates obtained is reacted with 1 to 1.5 mol equivalents of HNR2R3. The reaction is carried out in an alkanol having 1 to 3 carbon atoms at 0 to 100 DEG C. The novel compounds of the formulae I and II are administered orally to warm-blooded animals to improve the extent of the feed effect and to increase the growth rate. A supplementary feed for increasing the growth rate of poultry, fur-bearing animals and agricultural productive animals contains 70 to 99% by weight of an edible carrier and, as the remainder, a novel compound of the formula I or II.
BACKGROUND: Whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain.
METHODS: We conducted a randomized, controlled trial involving patients with heart failure and moderate to severe functional mitral regurgitation from 30 sites in nine countries. The patients were assigned in a 1:1 ratio to either transcatheter mitral-valve repair and guideline-recommended medical therapy (device group) or medical therapy alone (control group). The three primary end points were the rate of the composite of first or recurrent hospitalization for heart failure or cardiovascular death during 24 months; the rate of first or recurrent hospitalization for heart failure during 24 months; and the change from baseline to 12 months in the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS; scores range from 0 to 100, with higher scores indicating better health status).
RESULTS: A total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure or cardiovascular death was 37.0 events per 100 patient-years in the device group and 58.9 events per 100 patient-years in the control group (rate ratio, 0.64; 95% confidence interval [CI], 0.48 to 0.85; P = 0.002). The rate of first or recurrent hospitalization for heart failure was 26.9 events per 100 patient-years in the device group and 46.6 events per 100 patient-years in the control group (rate ratio, 0.59; 95% CI, 0.42 to 0.82; P = 0.002). The KCCQ-OS score increased by a mean (±SD) of 21.6±26.9 points in the device group and 8.0±24.5 points in the control group (mean difference, 10.9 points; 95% CI, 6.8 to 15.0; P<0.001). Device-specific safety events occurred in 4 patients (1.6%).
CONCLUSIONS: Among patients with heart failure with moderate to severe functional mitral regurgitation who received medical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or cardiovascular death and a lower rate of first or recurrent hospitalization for heart failure at 24 months and better health status at 12 months than medical therapy alone. (Funded by Abbott Laboratories; RESHAPE-HF2 ClinicalTrials.gov number, NCT02444338.).
This methodological research design is a prospective exploratory test-retest design assessing the use of electrodermal activity (EDA) as an index of sensory processing. EDA will be measured using skin conductance response (SCR). The purpose of this study is to investigate if using EDA is a reliable measure over time within the context of response to sensation. Scores from test one and test two of each subject will be correlated to determine reliability of EDA measure. Reliability in this context will establish the utility of EDA as an index of sensory processing. Testing will occur two times within a six week period.
Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
ETHNOPHARMACOLOGICAL RELEVANCE: Shuangshen Ningxin Formula (SSNX) is a traditional Chinese medicine formula used to treat myocardial ischemia-reperfusion injury (MIRI). A randomized controlled trial previously showed that SSNX reduced cardiovascular events, and experiments have also verified that SSNX attenuated ischemia-reperfusion (I/R) injury. However, the mechanism of SSNX in the treatment of microvascular I/R injury is still unclear.
AIM OF THE STUDY: To determine whether SSNX protects the microvasculature by regulating I/R induction in rats and whether this effect depends on the regulation of NR4A1/Mff/Drp1 pathway.
METHODS: The anterior descending coronary artery was ligated to establish a rat MIRI model with 45 min of ischemia and 24 h of reperfusion. The rats were subjected to a 7-day pretreatment with SSNX and nicorandil, after which their cardiac function and microvascular functional morphology were evaluated through diverse methods, including hematoxylin and eosin (HE) staining, wheat germ agglutinin (WGA) staining, and transmission electron microscopy. Cell apoptosis was assessed using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Additionally, serum levels of ET-1 and eNOS were determined through an enzyme-linked immunosorbent assay (ELISA). The expression levels of NR4A1, Mff, and proteins related to mitochondrial fission were examined by Western blot (WB). Cardiac microcirculation endothelial cells (CMECs) were cultured and the oxygen-glucose deprivation/reoxygenation (OGD/R) model was duplicated. Following treatment with SSNX and DIM-C-pPhOH, an NR4A1 inhibitor, cell viability was assessed. Fluorescence was used to evaluate mitochondrial membrane potential (MMP) and mitochondrial permeability transition pore (MPTP) opening. Moreover, vascular endothelial function was evaluated through transendothelial electrical resistance (TEER), Transwell assays and tube formation assays.
RESULTS: The results showed that SSNX reduced the infarction area and no-flow area, improved cardiac function, mitigated pathological alterations, increased endothelial nitric oxide synthase expression, protected endothelial function, and attenuated microvascular damage after I/R injury. I/R triggered mitochondrial fission and apoptotic signaling in CMECs, while SSNX restored mitochondrial fission to normal levels and inhibited mitochondrial apoptosis. A study using CMECs revealed that SSNX protected endothelial function after OGD/R, attenuating the increase in NR4A1/Mff/Drp1 protein and inactivating VDAC1, HK2, cytochrome c (cyt-c) and caspase-9. Research also shows that SSNX can affect CMEC cell migration and angiogenesis, reduce mitochondrial membrane potential damage, and inhibit membrane opening. Moreover, DIM-C-pPhOH, an NR4A1 inhibitor, partially imitated the effect of SSNX.
CONCLUSION: SSNX has a protective effect on the cardiac microvasculature by inhibiting the NR4A1/Mff/Drp1 pathway both in vivo and in vitro.
Common metallurgically produced materials are utilized in the production of dental products. During production, however, not all of the material can be utilized. When the material is subsequently processed by casting, a lot of energy is required for melting. The invention relates to a method for producing dental castings or a material for dental castings. According to the invention, fine particles of the material are to be partially fused and the fused particles are to be compacted. This results in a sintered semifinished product. During subsequent processing using casting techniques, this sintered semifinished product can be easily cast into dental castings in a pot of a casting device. The sintered semifinished product offers a good homogeneity during mechanical subsequent processing. The sintered semifinished products produced according to the inventive method are suited for all dental products which are produced by means of casting, especially for implant constituents, crowns, bridges and model casts.
Antibody-mediated rejection (ABMR) is one of the main obstacles to successful transplantation, including ABO blood group-incompatible (ABOi) transplantation. C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues. Described herein are anti-C4d CAR Tregs that suppress ABMR in ABOi allografts. Anti-C4d CAR Tregs prepared by retroviral transduction of CAR into CD62L +CD4 +CD25 +Tregs, expressed Foxp3, CD25, CTLA-4, LAP, and GITR to similar extents as non-transduced Tregs. Anti-C4d CAR Tregs were activated by specific binding to C4d and suppressed in vitro T cell proliferation as well as non-transduced Tregs. Furthermore, adoptive transfer of anti-C4d CAR Tregs significantly prolonged mouse ABOi heart allograft survival (P<0.05).
While seated, a rapid inflation cuff, similar to those used to measure blood pressure, will be placed around the paretic thigh to perform sham or fake ischemic conditioning. The pressure of the cuff will be increased for 5 minutes followed by no pressure for 5 minutes, repeated 5 times for a total of 50 minutes.
This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as "mindfulness in breathing", "body scan", "mindful walking", "mindful movements" and "3-minutes of mindfulness" and the concepts of "first and second suffering" and the "Hi-Thanks-Bye".
Cystic fibrosis (CF) is an autosomal recessive, multisystem involvement disease. The most important cause of mortality in CF is pulmonary complications. Prevention of pulmonary complications is only possible with pulmonary rehabilitation. Pulmonary rehabilitation methods used in CF are called airway cleaning techniques that include postural drainage, breathing techniques and use of devices. These techniques have not been proven to be superior to each other. Active cycle of breathing techniques (ACBT) is one of the breathing techniques used to remove secretions from the lungs.

Pulmonary disease progression in CF causes postural impairment and decrease of exercise tolerance, which can reduce effectiveness of pulmonary rehabilitation. The aim of this study is to investigate the effects of postural exercise program added to pulmonary rehabilitation program on quality of life, exercise tolerance and postural stability in children with CF.